Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

A Two-Part Study Evaluating the Combination of Tazemetostat and CPX-351 (Part 1) and Palbociclib with CPX-351 (Part 2) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Gina Keiffer, Bruno Calabretta, Alexander Mazo, Ubaldo Martinez Outschoorn, Onder Alpdogan, Adam F. Binder, Pierluigi Porcu, Lindsay Wilde, Margaret Kasner

Blood (2023) 142 (Supplement 1): 1550.

https://doi.org/10.1182/blood-2023-186671

Published: 2023

Journal Articles

Perceptions of a Home Blood Transfusion Program Among Patients with Hematologic Malignancies Who Are Newly Diagnosed As Compared to Those with Relapsed/Refractory Disease

Riyana Doshi, Karla Martin Gonzalez, Alavi Hossain, Alexzandra T Gentsch, Angelica Vivero, Lindsay Wilde, Kristin L Rising, Adam F. Binder

Blood (2023) 142 (Supplement 1): 2356.

https://doi.org/10.1182/blood-2023-185301

Published: 2023

Journal Articles

Characteristics and Clinical Outcomes of Patients with Acute Myeloid Leukemia with TP53 Mutations - a Single Center Experience

Xia Bi, Zoe Begun, Dolores A. Grosso, Margaret Kasner, Gina Keiffer, Joanne Filicko-O'Hara, William O'Hara, John L. Wagner, Lindsay Wilde, Neal Flomenberg, Zixuan Wang, Usama Gergis

Blood (2023) 142 (Supplement 1): 2847.

https://doi.org/10.1182/blood-2023-179931

Published: 2023

Journal Articles

A Phase Ib/II Study Evaluating Navitoclax after Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Gina Keiffer, Sara E. Meyer, Christine Eischen, Ubaldo Martinez Outschoorn, Onder Alpdogan, Adam F. Binder, Pierluigi Porcu, Lindsay Wilde, Margaret Kasner, Neil Palmisiano

Blood (2023) 142 (Supplement 1): 1551.

https://doi.org/10.1182/blood-2023-186765

Published: 2023

Journal Articles

Time to Treatment for Patients with Suspected Acute Promyelocytic Leukemia (APL)

Grant Jirka, Tara Rakiewicz, Navya George, Misung Yi, Margaret Kasner, Gina Keiffer, Lindsay Wilde

Blood (2023) 142 (Supplement 1): 5099.

https://doi.org/10.1182/blood-2023-177978

Published: 2023

Journal Articles

Tumor Lysis Syndrome in Patients with AML Initiated on Venetoclax-Based Treatment without a Dose Ramp-up

Zoe Begun, Emilie Thompson, Tingting Zhan, Gina Keiffer, Margaret Kasner, Lindsay Wilde

Blood (2023) 142 (Supplement 1): 3720.

https://doi.org/10.1182/blood-2023-184610

Published: 2023

Journal Articles

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML): A Multicenter Analysis of Safety and Healthcare Resource Utilization

Gina Keiffer, Guneet Kaleka, Caspian Oliai, Lindsay Wilde, Neil Palmisiano, Margaret Kasner

Blood (2022) 140 (Supplement 1): 3320–3321.

https://doi.org/10.1182/blood-2022-170710

Published: 2022

Journal Articles

Assessment of Concurrent Personal and Family History of Hematologic Malignancies in Patients Referred for Genetic Counseling at Thomas Jefferson University Hospital (TJUH), Sidney Kimmel Cancer Center (SKCC) from 2014-2021

Molly Halloran, Gina Keiffer, Veda Giri, Laura Gross, Lindsay Wilde, Neil Palmisiano, Pierluigi Porcu, Margaret Kasner

Blood (2022) 140 (Supplement 1): 11466–11467.

https://doi.org/10.1182/blood-2022-165510

Published: 2022

Journal Articles

Smoking and Its Prognostic Effect on Survival in Patients with TP53 Mutated MDS

Sean Patrick Reilly, Xia Bi, Zachary French, Lindsay Wilde, Neil Palmisiano

Blood (2022) 140 (Supplement 1): 12339–12340.

https://doi.org/10.1182/blood-2022-164712

Published: 2022

Journal Articles

Inpatient Versus Outpatient Hypomethylating Agent Induction for AML As a Predictor for Survival

Chetan Jeurkar, DO, Benjamin E Leiby, PhD, Joshua Banks, MS, Margaret Kasner, MDMSc, Gina Keiffer, MD, Lindsay Wilde, MD, Joanne Filicko-O'Hara, MD, Neil Palmisiano, MDMS

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-133837

Published: 2020

Journal Articles

Vaccination Response after Autologous Stem Cell Transplantation

Onder Alpdogan, MD, Jennifer Hong, MD, Thomas R. Klumpp, MD, Abdullateef O Abdulkareem, MD MPH, Adam F. Binder, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Dolores Grosso, DNP, CRNP, Margaret Kasner, MDMSc, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MDMS, Lindsay Wilde, MD, Pierluigi Porcu, MD, Usama Gergis, MD, John L. Wagner, MD, Neal Flomenberg, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-141269

Published: 2020

Journal Articles

Results of the Phase 1b Dose Escalation Study of OPB-111077, Decitabine, and Venetoclax for the Treatment of Newly Diagnosed or Relapsed/Refractory AML

Lindsay Wilde, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MDMS, Gina Keiffer, MD, Margaret Kasner, MDMSc

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-140729

Published: 2020

Journal Articles

Impact of Smoking and TP53 Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Xia Bi, MD MS, Zachary French, MD, Margaret Kasner, MDMSc, Gina Keiffer, MD, Lindsay Wilde, MD, Neil Palmisiano, MDMS

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-141640

Published: 2020

Journal Articles

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML) Is Safe and Yields Healthcare Resource Savings

Gina Keiffer, MD, Kelly Hughes, Tingting Zhan, PhD, Lindsay Wilde, MD, Neil Palmisiano, MDMS, Margaret Kasner, MDMSc

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-140055

Published: 2020

Journal Articles

Socioeconomic Influences on the Treatment and Outcomes of Patients with Acute Myeloid Leukemia: Experience from an Urban Academic Center

Jonathan Pan, MD, Sushil Ghimire, MD, Molly Halloran, MD, Alexander Xu, BA, Tingting Zhan, PhD, Gina Keiffer, MD, Lindsay Wilde, MD, Neil Palmisiano, MDMS, Margaret Kasner, MDMSc, Adam F. Binder, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-143146

Published: 2020

Journal Articles

COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience

Lindsay Wilde, MD, Adam F. Binder, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, John L. Wagner, MD, Onder Alpdogan, MD, Margaret Kasner, MDMSc, Thomas R. Klumpp, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MDMS, Gina Keiffer, MD, Dolores Grosso, DNP, CRNP, Michael Millenson, Amy R. MacKenzie, MD, Allison Zibelli, MD, Neal Flomenberg, MD, Pierluigi Porcu, MD, Usama Gergis, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-140719

Published: 2020

Journal Articles

OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia

Lindsay Wilde, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MD MS, Margaret Kasner, MDMSc

Blood (2019) 134 (Supplement_1): 2597.

https://doi.org/10.1182/blood-2019-131979

Published: 2019

Journal Articles

A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)

Neil Palmisiano, MD, Grace Jeschke, PhD, Lindsay Wilde, MD, Benjamin E Leiby, PhD, Onder Alpdogan, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Dolores Grosso, DNP, CRNP, Thomas R. Klumpp, MD, Ubaldo Martinez Outschoorn, MD, John L Wagner, MD, Martin Carroll, MD, Pierluigi Porcu, MD, Neal Flomenberg, MD, Alexander E. Perl, MD, Margaret Kasner, MD

Blood (2017) 130 (Supplement 1): 4267.

https://doi.org/10.1182/blood.V130.Suppl_1.4267.4267

Published: 2017

NARROW

A Two-Part Study Evaluating the Combination of Tazemetostat and CPX-351 (Part 1) and Palbociclib with CPX-351 (Part 2) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Perceptions of a Home Blood Transfusion Program Among Patients with Hematologic Malignancies Who Are Newly Diagnosed As Compared to Those with Relapsed/Refractory Disease

Characteristics and Clinical Outcomes of Patients with Acute Myeloid Leukemia with TP53 Mutations - a Single Center Experience

A Phase Ib/II Study Evaluating Navitoclax after Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Time to Treatment for Patients with Suspected Acute Promyelocytic Leukemia (APL)

Tumor Lysis Syndrome in Patients with AML Initiated on Venetoclax-Based Treatment without a Dose Ramp-up

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML): A Multicenter Analysis of Safety and Healthcare Resource Utilization

Assessment of Concurrent Personal and Family History of Hematologic Malignancies in Patients Referred for Genetic Counseling at Thomas Jefferson University Hospital (TJUH), Sidney Kimmel Cancer Center (SKCC) from 2014-2021

Smoking and Its Prognostic Effect on Survival in Patients with TP53 Mutated MDS

Inpatient Versus Outpatient Hypomethylating Agent Induction for AML As a Predictor for Survival

Vaccination Response after Autologous Stem Cell Transplantation

Results of the Phase 1b Dose Escalation Study of OPB-111077, Decitabine, and Venetoclax for the Treatment of Newly Diagnosed or Relapsed/Refractory AML

Impact of Smoking and TP53 Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML) Is Safe and Yields Healthcare Resource Savings

Socioeconomic Influences on the Treatment and Outcomes of Patients with Acute Myeloid Leukemia: Experience from an Urban Academic Center

COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience

OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia

A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only